Dennis M. Lanfear - Jan 4, 2022 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Signature
/s/ McDavid Stilwell, as Attorney-in-Fact for Dennis M. Lanfear
Stock symbol
CHRS
Transactions as of
Jan 4, 2022
Transactions value $
$0
Form type
4
Date filed
1/6/2022, 06:50 PM
Previous filing
Nov 23, 2021
Next filing
Jan 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CHRS Common Stock Award $0 +86.3K +17.49% $0.00 580K Jan 4, 2022 Direct F1, F2
holding CHRS Common Stock 437K Jan 4, 2022 By Trust F3
holding CHRS Common Stock 87K Jan 4, 2022 By LLC F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Award $0 +403K $0.00 403K Jan 4, 2022 Common Stock 403K $15.94 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 4 of each year, with the first 1/3 vesting on January 4, 2023 and with the RSUs being fully vested on January 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F2 Includes 86,250 RSUs.
F3 These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee.
F4 These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President.
F5 The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.